Tiziana Life Sciences is trading 5.8% up at $0.94, with broader biotech strength the clearest available explanation during September 23, 2026 trading.
- No new company-specific announcement was identified for September 23.
- The latest material update was completion of the INFORM-MS Phase 2a trial’s final patient visit; topline 12-week data are expected in October. This may support sentiment but does not directly explain the move.
- The stock opened during an otherwise weaker broad-market session.